Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era.

Clinical lymphoma, myeloma & leukemia - 1 Jun 2026

Jinguji Atsushi, Kurosawa Shuhei, Toya Takashi, Kato Kana, Sadaga Yasutaka, Kondo Kaori, Ouchi Fumihiko, Shimabukuro Masashi, Shingai Naoki, Shimizu Hiroaki, Najima Yuho, Haraguchi Kyoko, Doki Noriko

Abstract excerpt

BACKGROUND: FLT3 mutations in acute myeloid leukemia (AML) are associated with high relapse rates even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). OBJECTIVES: We evaluated changes in transplant outcomes in patients with FLT3-ITD-mutated AML and detailed real-world experiences with post-transplant gilteritinib maintenance. STUDY DESIGN: This study included adult patients (≥16 years) with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Protein Kinase Inhibitors

Share to Pyrazines

Share to Transplantation, Homologous

Share to Treatment Outcome

Source

Identifiers

PMID: 41966917
DOI: 10.1016/j.clml.2026.03.007

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era.PMID 41966917Read ↗

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutationSemantic proximity Read ↗

Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.Semantic proximity Read ↗

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.Semantic proximity Read ↗

FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.Semantic proximity Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.Semantic proximity Read ↗

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.Semantic proximity Read ↗

[Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].Semantic proximity Read ↗

FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AMLSemantic proximity Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.